DG Comp reviews pay-for-delay settlements
Tuesday, 12 January 2010
Emily Gray
The European Commission is monitoring patent settlements between drug companies, after its pharmaceutical sector inquiry flagged the agreements as potentially anti-competitive.
PREMIUM Subscription required to view this article
This content can only be accessed by PREMIUM GCR subscribers.
A premium subscription includes 10 issues of the journal, 2 signature surveys - The GCR100 and Rating Enforcement, 10 GCR special reports and full access to current and archived print & online content.
If you are a GCR subscriber, please login to access this content:
Comments
You must Subscribe or Log In to make comments.
Comment Terms & Conditions
Back to top